Results 221 to 230 of about 36,434 (294)

Intranasal Galanin (1-15) modulates alcohol self-administration and depressive-like behavior in rats and shows a favorable safety profile. [PDF]

Front Pharmacol
Cantero-García N, Flores-Burgess A, Flores-Gómez M, Pineda-Gómez JP, Ramos MC, Diaz C, Millón C, Díaz-Cabiale Z.   +7 more
europepmc   +1 more source

Modeling study of hERG facilitation effect by nifekalant

, 2019
Kunichika Tsumoto, Kazuharu Furutani, Yoshihisa Kurachi   +2 more
openalex   +2 more sources

Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular-Respiratory Pharmacology, and Single/Repeated-Dose Toxicity in Beagle Dogs. [PDF]

Biomedicines
Gu X, Li X, Li H, Liu N, Xu Y, Li K, Zhang J, Wang X, Zhang X, Ding Y, Zhou H, Ai X, Yang C.   +12 more
europepmc   +1 more source

Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients. [PDF]

Clin Transl Sci
Poon V, Sutaria D, Prell R, Halpern W, Wong L, Harris A, Wilkins J, Yoshida K, Sane R.   +8 more
europepmc   +1 more source

Self-assembling dendrimer nanodrug formulations for decreased hERG-related toxicity and enhanced therapeutic efficacy. [PDF]

Sci Adv
Liu X, Dhumal D, Santofimia-Castaño P, Liu J, Casanova M, Garcia-Muñoz AC, Perles-Barbacaru TA, Elkihel A, Zhang W, Roussel T, Galanakou C, Wu J, Zerva E, Dusetti N, Xia Y, Liang XJ, Viola A, Iovanna JL, Peng L.   +18 more
europepmc   +1 more source

Nutritional Factors and Arrhythmic Risk in Long QT Syndrome: A Narrative Review of Mechanistic and Clinical Evidence. [PDF]

Adv Nutr
Mazzanti A, Floriano M, Kukavica D, Trancuccio A, Priori SG.   +4 more
europepmc   +1 more source

Erratum: HERG K+ Channel Blockade by the Novel Antiviral Drug Sophocarpine [Biol. Pharm. Bull. 31(4): 627-632 (2008)]

, 2009
Xue-Ling Zhao, Zhiping Qi, Cheng Fang, Minghong Chen, Yanjie Lv, Baoxin Li, Baofeng Yang   +6 more
openalex   +2 more sources

Modelling of clinical TQT studies outcomes from preclinical cardiovascular safety pharmacology studies using the one-step QTc model. [PDF]

Front Pharmacol
Champéroux P, Fares R, Leishman D.
europepmc   +1 more source

FDA's insights: implementing new strategies for evaluating drug-induced QTc prolongation. [PDF]

J Pharmacokinet Pharmacodyn
Ji Y, Johannesen L, Garnett C.
europepmc   +1 more source

The Cardiac Sodium Channel Safety Profile of Cenobamate at Therapeutic Concentrations: In Vitro Analyses. [PDF]

Clin Transl Sci
Crumb WJ, Melnick SM, Glenn KJ.
europepmc   +1 more source